FTSE MIB
33.503,39 -450,89 (-1,33%) Dow Jones
37.959,96 +224,85 (+0,60%) Nasdaq
15.873,67 -11,34 (-0,07%) Nikkei 225
38.471,20 -761,60 (-1,94%) Petrolio
85,34 -0,07 (-0,08%) Bitcoin EUR
59.492,51 -2.725,80 (-4,38%)
HOOKIPA Pharma Inc. (HOOK)
| Chiusura precedente | 0,7600 |
| Aperto | 0,7500 |
| Denaro | 0,5250 x 200 |
| Lettera | 0,9880 x 200 |
| Min-Max giorno | 0,7500 - 0,7502 |
| Intervallo di 52 settimane | 0,4100 - 2,0500 |
| Volume | |
| Media Volume | 554.356 |
| Capitalizzazione | 74,232M |
| Beta (5 anni mensile) | 1,02 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8600 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,70 |
GlobeNewswireHOOKIPA Announces Executive Leadership Change
NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim
- GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 100,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement m
- GlobeNewswire
HOOKIPA Pharma to participate in upcoming investor conferences in September
NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences: Morgan Stanley Global Healthcare Conference, September 11-13, New YorkFireside Chat: Monday, September 11, 3:35pm ET H.C. Wainwright Global Investment Conferenc
